N-cadherin inhibitor creates a microenvironment that protect TILs from immune checkpoints and Treg cells

Abstract

These data show that the N-cadherin antagonist ADH-1 promotes TIL antitumor responses. This important hurdle must be overcome for tumors to respond to immunotherapy.